文献速递乳房整形与再造

代谢综合征对乳房再造决策及术后结局的影响:一项全国性分析

The impact of metabolic syndrome in breast reconstruction decision-making and postoperative outcomes: A nationwide analysis.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2023-11-29

基于ACS-NSQIP数据库2012至2021年160115例乳房再造患者,其中4570例有代谢综合征。代谢综合征组术后伤口并发症风险(OR 2.21;95%CI 1.399, 3.478;p=0.001)和再入院率(OR 2.045;95%CI 1.337, 3.128;p=0.001)高于非代谢综合征组,再造类型无显著差异。作者认为该人群可考虑延期乳房再造而非即刻乳房再造。

要点

  • 代谢综合征组术后伤口并发症风险升高(OR 2.21;95%CI 1.399, 3.478;p=0.001)。
  • 代谢综合征组再入院风险升高(OR 2.045;95%CI 1.337, 3.128;p=0.001)。
  • 两组乳房再造类型无统计学显著差异,其他术后并发症无显著差异。

核心结论

  • 代谢综合征患者乳房再造后伤口并发症和再入院风险似乎升高。
  • 作者认为应将该代谢综合征作为整体状况处理,并考虑在该人群中选择延期乳房再造而非即刻乳房再造。
  • 作者认为在乳房再造各阶段整合代谢综合征管理和患者咨询可能改善结局并促进患者决策。

研究设计与样本

  • 利用ACS-NSQIP数据库识别2012年至2021年间接受乳房再造的女性。
  • 共纳入160115例患者,其中4570例有代谢综合征,155545例无代谢综合征。
  • 代谢综合征定义为因糖尿病和高血压接受药物治疗且体重指数大于30 kg/m2。
  • 组间差异采用t检验和Fisher精确检验评估,术后并发症采用多因素逻辑回归模型评估。

主要发现

  • 两组乳房再造类型无统计学显著差异。
  • 代谢综合征组术后伤口并发症风险高于非代谢综合征组(OR 2.21;95%CI 1.399, 3.478;p=0.001)。
  • 代谢综合征组再入院风险高于非代谢综合征组(OR 2.045;95%CI 1.337, 3.128;p=0.001)。
  • 两组其他术后并发症无显著差异。

临床怎么用

  • 作者认为在该人群中可考虑选择延期乳房再造而非即刻乳房再造。
  • 作者认为在乳房再造各阶段整合代谢综合征管理和患者咨询可能改善结局并促进患者决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic syndrome (MetS) is a cluster of cardiometabolic abnormalities including hypertension, obesity, insulin resistance, and dyslipidemia. The safety profiles of patients with MetS undergoing breast reconstruction remain underreported. This study aims to evaluate the impact of MetS on the BR decision-making process and postoperative complication rates. METHODS: The ACS-NSQIP database was utilized to identify women who underwent BR between 2012 and 2021. Baseline characteristics were compared based on the presence of MetS, defined as patients receiving medical treatment for diabetes mellitus and hypertension, with a body mass index greater than 30 kg/m2. Group differences were assessed using t tests and Fisher's exact tests. Multivariate logistic regression models evaluated postoperative complications between the groups. RESULTS: A total of 160,115 patients underwent BR. A total of 4570 had a diagnosis of MetS compared to 155,545 without MetS. No statistically significant differences were observed in the type of BR patients received across cohorts. Logistic regression models demonstrated a higher likelihood of postoperative wound complications (OR 2.21; 95% CI 1.399, 3.478; p = 0.001), and readmission rates (OR 2.045; 95% CI 1.337, 3.128; p = 0.001) in the MetS group compared to the non-MetS patients. No significant differences were identified in other postoperative complications between groups. CONCLUSIONS: Patients with MetS appear to have an increased risk of postoperative wound complications and readmission after breast reconstruction. The synergistic effects of these comorbidities on postoperative outcomes underscore the importance of addressing MetS as a holistic condition and considering choosing Delayed breast reconstruction over Immediate Breast Reconstruction in this population. Thus, integrating MetS management and patient counseling at various stages of BR may improve outcomes and facilitate patient decision-making.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Escobar-Domingo MJ, Bustos VP, Kim EJ, et al. The impact of metabolic syndrome in breast reconstruction decision-making and postoperative outcomes: A nationwide analysis. J Plast Reconstr Aesthet Surg. 2023. PMID: 38128370. doi:10.1016/j.bjps.2023.11.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。